An­tibi­ot­ic de­vel­op­er scores $50M from biotech bil­lion­aire; Bio­haven's Alzheimer's drug pass­es fu­til­i­ty test

6 years ago
News Briefing

Ex-Cel­gene ex­ec Ter­rie Cur­ran puts her Phath­om team in place; Car­away taps Mar­tin Williams as CEO

6 years ago
Peer Review

UCB buffs up in block­buster pso­ri­a­sis race as bimek­izum­ab beats Hu­mi­ra in head-to-head

6 years ago
R&D

With EMA re­view in progress, No­var­tis un­veils more pos­i­tive da­ta on asth­ma ther­a­py

6 years ago
R&D

Black Di­a­mond rais­es an­oth­er $85M to bring new onco­gene ap­proach in­to clin­ic

6 years ago
Financing

One of Wall Street’s most high-pro­file hedge funds push­es Alex­ion's CEO to the auc­tion block — and he's not ...

6 years ago
People

With FDA re­view of its gene ther­a­py un­der­way, Fer­ring's $570M spin­out de­liv­ers in PhI­II blad­der can­cer read­out

6 years ago
R&D
Cell/Gene Tx

On the heels of a PhI­II im­plo­sion, can­cer biotech Molo­gen is turned over to the liq­uida­tor

6 years ago
R&D

While No­var­tis com­bats gener­ic on­slaught in the courts, FDA ap­proves first Gilenya copy­cats

6 years ago
Pharma
FDA+

The fu­ture of Ipsen’s new $1.3B drug is in doubt as safe­ty fears force the FDA to slam the brakes on late-stage ...

6 years ago
R&D
FDA+

Sue Desmond-Hell­mann says it's time for her to leave the Gates Foun­da­tion. Strat­e­gy chief Mark Suz­man will now take ...

6 years ago
People

Skep­tics pounce as Bio­gen de­tails pos­i­tive sub­group analy­sis on ad­u­canum­ab — and both sides are dig­ging in

6 years ago
R&D

As­traZeneca, Mer­ck score Chi­na OK for Lyn­parza; Re­gen­eron spot­lights mid-stage da­ta for rare dis­ease drug

6 years ago
News Briefing

Vivek Ra­maswamy’s En­zy­vant is hit with a CRL for man­u­fac­tur­ing — de­lay­ing a new ther­a­py for an ul­tra-rare killer

6 years ago
R&D

Daphne Koller's AI start­up ends wide search for a da­ta chief, tap­ping Stan­ford's Ser­afim Bat­zoglou for the job

6 years ago
R&D

No­var­tis CEO Vas Narasimhan's R&D up­date spot­lights next wave of drug stars as well as late-stage fa­vorites

6 years ago
R&D

Michael Ehlers teas­es plan to build the next 'sig­na­ture' ge­net­ic med­i­cine com­pa­ny with $75M from Ap­ple Tree Part­ners

6 years ago
R&D

A biotech emerges from one Deer­field­'s R&D do­na­tion part­ners

6 years ago
R&D

Aca­dia un­veils the pos­i­tive PhI­II it's tak­ing to FDA for ex­pand­ing Nu­plazid's use in psy­chosis

6 years ago
R&D

Putting the safe­ty is­sue to bed, Au­rini­a's late-stage lu­pus nephri­tis da­ta shines

6 years ago
R&D

Sage's star ex­per­i­men­tal de­pres­sion drug fails the cru­cial MOUN­TAIN study — shares crash

6 years ago
R&D

Josh Bilenker and his Loxo crew are tak­ing the reins on on­col­o­gy R&D at Eli Lil­ly, culling the weak and map­ping a new ...

6 years ago
R&D

Near­ly a year af­ter sur­prise re­jec­tion, Im­munomedics re­turns to FDA

6 years ago
R&D

Cell, gene ther­a­py man­u­fac­tur­ing takes cen­ter stage as No­var­tis, Ama­zon join forces

6 years ago
R&D
First page Previous page 887888889890891892893 Next page Last page
A service from the Financial Times